Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proglumetacin SCHEMBL27106 | 1.00 | PTGS2 (0.59) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL19642980 | 0.97 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL1650599 | 0.97 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL99165 | 0.97 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL2070226 | 0.97 | PTGS2 (0.55) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL28086382 | 0.97 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL5077578 | 0.91 | PTGS2 (0.57) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL4094289 | 0.91 | PTGS2 (0.52) | PTGS2 | |
| Proglumetacin SCHEMBL13724384 | 0.91 | PTGS2 (0.49) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL5482765 | 0.89 | PTGS2 (0.47) | PTGS2HTR1APKMPTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132131-A1 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | VTV THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12545676-B2 | Crystalline form of hydrochloride salt of quinoline derivative | VTV THERAPEUTICS LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-12377144-B2 | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | DRAGONFLY THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250002852-A1 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | DARTMOUTH COLLEGE (US) | 2025-01-02 | — | — | US | disclosed |
| US-20230405003-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| US-20230312559-A1 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| EP-4238571-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | OnQuality Pharmaceuticals China Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| CN-116529247-A | Crystal forms of hydrochloride of quinoline derivative | 维特卫治疗有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4188386-A1 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | vTv Therapeutics LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4175955-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | vTv Therapeutics LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230034186-A1 | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | DRAGONFLY THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022026350-A1 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | VTV THERAPEUTICS LLC (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545676-B2 | Crystalline form of hydrochloride salt of quinoline derivative | IL1B, IL1A, NOD2 | PTGS2 179/4885HTR1A 1215/4885PKM 1942/4885 |
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | NQO2, STAT6, TPMT | PTGS2 173/4885HTR1A 431/4885PKM 3425/4885 |
| US-20230312559-A1 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | UACA, NOD2, SSB | PTGS2 402/4885HTR1A 1192/4885PKM 4657/4885 |
| US-20230405003-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | TYMP, DCTD, TYMS | PTGS2 2726/4885HTR1A 1501/4885PKM 2923/4885 |
| US-20260132131-A1 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | IL1B, IL1A, NLRP3 | PTGS2 645/4885HTR1A 658/4885PKM 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.